Approved indication: Inbrija is approved as an on‑demand treatment for intermittent OFF episodes (the return of Parkinson’s symptoms between scheduled doses) in adults with Parkinson’s disease who are already on a carbidopa/levodopa regimen, and it is not intended to replace their regular daily Parkinson’s medications.

Off‑label use: There are no well‑established off‑label indications specific to inhaled levodopa; outside clinical trials, its use is generally limited to specialist‑directed rescue treatment of OFF episodes in patients similar to those in the approved indication.

Efficacy expectations: In clinical studies, many patients began to improve as early as about 10 minutes after inhalation, with significantly greater improvement in motor scores than placebo at 30 minutes and more patients returning to and staying in the ON state for at least 60 minutes; in practice it is used as a rescue option comparable in overall benefit to other on‑demand therapies for OFF episodes, but with the familiar levodopa mechanism and without injections.

Typical dosing and how to take it: For adults, the recommended dose is 84 mg (two 42‑mg capsules) taken by oral inhalation at the start of an OFF episode, using only the supplied Inbrija inhaler, loading and inhaling one capsule at a time; do not swallow the capsules, do not use more than one 84‑mg dose per OFF period, and do not exceed five doses (10 capsules, 420 mg) in a day.

Administration tips and special instructions: Sit or stand upright, load a single capsule into the inhaler, seal your lips around the mouthpiece, and breathe in slowly and deeply enough to hear or feel the capsule whirl (you may need more than one breath per capsule); you may sip water before or after use to ease throat irritation, and you should continue all of your regular scheduled Parkinson’s medicines, since Inbrija is for as‑needed rescue only.

Missed dose and overdose guidance: Because Inbrija is used when symptoms return rather than on a fixed schedule, there is no usual “missed dose,” but if you still feel OFF soon after a dose, wait until the next OFF episode and do not repeat the dose immediately; if you accidentally exceed the maximum daily amount or develop severe nausea, abnormal movements, confusion, chest pain, very irregular heartbeat, or fainting, seek emergency care or contact poison control right away.

Common side effects: The most frequent side effects are cough, upper respiratory or cold‑like symptoms, nausea, discolored or darker saliva or sputum, and a sensation of throat irritation or choking right after inhalation; these usually appear early in treatment, are often mild to moderate, and may lessen over time while treatment continues.

Serious or rare adverse effects: Seek immediate medical attention for chest tightness or trouble breathing, severe or persistent coughing or wheezing, signs of allergic reaction (such as rash, swelling, or difficulty breathing), new or markedly increased uncontrolled movements, severe confusion or hallucinations, very high or very low blood pressure, or strong new compulsive behaviors like gambling or binge eating.

Warnings and precautions: Inbrija must not be used with nonselective monoamine oxidase (MAO) inhibitors taken within the past 14 days, and it is generally not recommended for people with asthma, COPD, or other chronic lung disease because of the risk of bronchospasm; caution is required in patients with glaucoma, serious heart or blood pressure problems, a history of psychosis or hallucinations, or significant daytime sleepiness, and its safety has not been established in pregnancy, breastfeeding, or children.

Overall safety profile and reporting: Systemic side effects are similar to those of other levodopa products (such as dyskinesia, low blood pressure, hallucinations, and impulse‑control problems), with additional local respiratory effects from inhalation, and one‑year data in patients without chronic lung disease have not shown a greater average decline in lung function than in controls; side effects can be reported to the FDA through the MedWatch program or to the manufacturer, and up‑to‑date safety information is available from the FDA and official Inbrija resources.

Drug and supplement interactions: Inbrija is contraindicated with nonselective MAO inhibitors taken within the previous 14 days, and caution is needed when it is combined with selective MAO‑B inhibitors, other dopaminergic medicines (which may increase dyskinesia or hallucinations), blood pressure–lowering drugs (which may worsen orthostatic hypotension), iron‑containing supplements or multivitamins (which can reduce levodopa absorption if taken together), and dopamine‑blocking agents such as many antipsychotics and some anti‑nausea drugs, which can oppose its effects.

Food, alcohol, and procedures: Because the medicine is inhaled rather than swallowed, food has less impact than with oral levodopa, but very high‑protein diets can still influence overall levodopa response; alcohol can add to dizziness, low blood pressure, or drowsiness and is best limited, and you should tell surgeons, anesthesiologists, and other clinicians that you use inhaled levodopa before new procedures or imaging that involves sedation or contrast.

Precautions and monitoring: Use is generally avoided in people with asthma, COPD, or other significant lung disease, and clinicians may check lung function and monitor for new or worsening respiratory symptoms; blood pressure, mental status, eye pressure in patients with glaucoma, involuntary movements, and impulse‑control behaviors should be reviewed periodically, and patients should not drive or perform hazardous tasks if they experience excessive sleepiness or sudden sleep attacks while on this medicine.

Q: What is Inbrija used for?
A: Inbrija is an inhaled levodopa medicine used as needed to treat OFF episodes—the return of Parkinson’s symptoms— in adults who are already taking carbidopa/levodopa.

Q: How fast does Inbrija start working?
A: Many people begin to notice some relief within about 10 minutes after inhalation, with peak improvement in motor symptoms typically seen around 30 minutes.

Q: How often can I use Inbrija in a day?
A: You may take one dose (two capsules) for an OFF episode and use it up to five times in a waking day, but you should not take more than one dose per OFF period or more than 10 capsules in 24 hours.

Q: Does Inbrija replace my regular Parkinson’s medicines?
A: No, Inbrija is an add‑on rescue treatment for OFF episodes and must be used together with, not instead of, your regular carbidopa/levodopa and any other Parkinson’s medications.

Q: Can I use Inbrija if I have asthma or COPD?
A: Inbrija is generally not recommended for people with asthma, COPD, or other chronic lung diseases because inhaling it can trigger bronchospasm or breathing problems, so your doctor will usually choose another OFF‑episode treatment if you have these conditions.

Q: Is Inbrija safe for children or during pregnancy?
A: Inbrija has been studied only in adults, and there is limited information in pregnancy or breastfeeding, so its use in children or during pregnancy or lactation is decided case by case by a specialist after weighing potential risks and benefits.

Storage: Store the inhaler and capsules in a dry place at room temperature 68°–77°F (20°–25°C), keep capsules in their original blister packs until just before use, do not store capsules inside the inhaler, and protect the medicine from moisture and extreme temperatures.

Disposal: Discard the inhaler after all capsules in the carton have been used, keep all parts out of the reach of children and pets, and use a pharmacy or community drug take‑back program or follow pharmacist/local guidance to dispose of unused or expired capsules instead of throwing them loose in household trash or flushing them.